Cocrystal Pharma (NASDAQ:COCP) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Cocrystal Pharma (NASDAQ:COCP) issued its quarterly earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.23, Zacks reports.

Cocrystal Pharma Trading Down 1.0 %

COCP traded down $0.02 during trading hours on Monday, hitting $1.47. The company’s stock had a trading volume of 3,783 shares, compared to its average volume of 29,036. Cocrystal Pharma has a 12 month low of $1.35 and a 12 month high of $3.26. The business’s 50-day moving average price is $1.81 and its 200-day moving average price is $1.93. The stock has a market cap of $14.90 million, a price-to-earnings ratio of -0.79 and a beta of 2.35.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Cocrystal Pharma in a research note on Wednesday, January 22nd.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.